Template:Formulations and brand names of norethisterone and esters
Jump to navigation
Jump to search
Composition | Dose | Brand names | Use |
---|---|---|---|
NET only | Low (e.g., 0.35 mg) | Multiple[lower-alpha 1] | Progestogen-only oral contraceptive |
NET or NETA only | High (e.g., 5 mg, 10 mg) | Multiple[lower-alpha 2] | Gynecological disorders and other uses |
NETE only | Injection (e.g., 200 mg) | Multiple[lower-alpha 3] | Progestogen-only injectable contraceptive |
NET or NETA with ethinylestradiol | Low (e.g., 0.4 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg) | Multiple[lower-alpha 4] | Combined oral contraceptive |
NET with mestranol | Low (e.g., 1 mg, 2 mg) | Multiple[lower-alpha 5] | Combined oral contraceptive |
NETA with estradiol | Low (e.g., 0.1 mg, 0.5 mg) | Multiple[lower-alpha 6] | Combined menopausal hormone therapy |
NETE with estradiol valerate | Injection (e.g., 50 mg) | Multiple[lower-alpha 7] | Combined injectable contraceptive |
Abbreviations: NET = Norethisterone. NETA = Norethisterone acetate. NETE = Norethisterone enanthate. Sources: [1][2][3][4] Notes:
|
References
- ↑ https://www.drugs.com/international/norethisterone.html
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 27 November 2016.
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 749–. ISBN 978-3-88763-075-1.
- ↑ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer (1 January 1999). Hormonal Contraception and Post-menopausal Hormonal Therapy (PDF). IARC. p. 65. ISBN 978-92-832-1272-0. Lay summary.
{{cite book}}
: Cite uses deprecated parameter|lay-url=
(help)